WHO Warns Global Antimicrobial Resistance Efforts Remain Off Track for 2030 Targets Despite Progress
Global efforts to combat antimicrobial resistance (AMR) have expanded, with more countries adopting national action plans, but implementation and funding gaps continue to threaten progress towards the 2030 targets, the World Health Organization (WHO) has
Global efforts to combat antimicrobial resistance (AMR) have expanded, with more countries adopting national action plans, but implementation and funding gaps continue to threaten progress towards the 2030 targets, the World Health Organization (WHO) has warned.
According to the WHO’s 2026 assessment, 173 of the 183 countries surveyed reported having a national action plan to tackle AMR, compared with just 79 countries in 2017. However, only 42 countries said their plans were both financed and implemented, highlighting the gap between policy commitments and action on the ground.
Antimicrobial resistance occurs when bacteria and other microorganisms evolve to withstand medicines designed to treat infections. The misuse and overuse of antibiotics and other antimicrobials accelerate this process, making infections harder to treat and increasing the risks associated with routine medical procedures.
The WHO highlighted major shortcomings in infection prevention and control. Although 128 countries now have national infection prevention and control programmes and guidelines, up from 90 in 2018, only 69 countries, or 38%, have implemented these programmes nationwide. This remains substantially below the global target of 90% by 2030.
Diagnostic capacity is another critical concern. While 131 countries reported having national reference laboratories capable of testing antibiotic resistance in common bacteria, only 66 could test for both bacterial and fungal resistance. Countries have committed to ensuring that 80% have this capacity by 2030. To strengthen laboratory capabilities, the WHO has released two diagnostic toolkits, including one outlining essential tests and another containing 73 laboratory procedures covering sample collection, pathogen identification and antibiotic susceptibility testing.
Surveillance systems have also expanded. The number of countries monitoring antibiotic use increased to 113 from 65 in 2017, while those tracking antimicrobial resistance rose to 109 from 39. However, only 21 countries reported integrating data on antibiotic consumption and resistance, limiting the ability to understand how medicine use contributes to the spread of resistance.
The scale of the threat remains significant. WHO data indicate that one in six laboratory-confirmed bacterial infections is resistant to antibiotics. If current trends continue, drug-resistant infections could contribute to more than 39 million deaths worldwide over the next 25 years. The organisation has also warned that the development of new antibiotics is not keeping pace with the spread of resistance.
The findings underline the need for sustained financing, stronger infection prevention, improved laboratory and surveillance systems, responsible antimicrobial use and greater investment in new treatments. Without faster implementation, countries risk falling short of the commitments made to contain AMR by 2030.
.
By MedGate Bureau

